Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Cancer Female × palbociclib × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 170 Neoplasm Metastasis 18 Ovarian Neoplasms 7 Neoplasms 7 Breast Diseases 6 Triple Negative Breast Neoplasms 3 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Neoplasms by Site 3 Head and Neck Neoplasms 3 Endometrial Neoplasms 3 Advanced Breast Cancer 3 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma 2 Recurrence 2 Neoplasm, Residual 2 Lung Neoplasms 2 Inflammation 2 Hereditary Sensory and Autonomic Neuropathies 2 Fallopian Tube Neoplasms 2 Estrogen Receptor-positive Breast Cancer 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Cardiovascular Diseases 2 Carcinoma, Ovarian Epithelial 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms, Male 2 Brain Neoplasms 2 Venous Thromboembolism 1 Uterine Cervical Neoplasms 1

Interventions

Tamoxifen 4 Exercise 3 pyrotinib 2 abemaciclib 2 Paclitaxel 2 Metformin 2 Cyclophosphamide 2 Capecitabine 2 Bupivacaine 2 Aromatase Inhibitors 2 pembrolizumab 1 pegylated granulocyte colony-stimulating factor 1 pegfilgrastim 1 palbociclib 1 iniparib 1 exemestane 1 durvalumab 1 darolutamide 1 Yoga 1 Waiting Lists 1 Vitamin D 1 Tumor Burden 1 Tretinoin 1 Trastuzumab 1 Tocopherols 1 Thioctic Acid 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1 Standard of Care 1 Sodium Chloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03065621 2023-04-19

NeoRHEA

Jules Bordet Institute

Phase 2 Completed

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡